An advisory panel at the US Food and Drug Administration recommended approval of an eagerly awaited vaccine for Lyme disease, a potentially fatal illness afflicting about 15,000 Americans each year, primarily in the suburban north-east and Midwest. The vaccine is called LYMErix and produced by SmithKline Beecham.